US · ADVB
Advanced Biomed Inc. Common Stock
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- New York City, NY 10168
- Website
- advanbiomed.com
Price · as of 2025-06-30
$5.27
Market cap 4.4M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 | |||||
| 2025 | $8.36 |
AI valuation
Our deep-learning model estimates Advanced Biomed Inc. Common Stock's (ADVB) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- $5.27
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ADVB | Advanced Biomed Inc. Comm… | $5.27 | 4.4M | — | — | — | — | -1690.19 | 0.05 | — | — | -7324.16 | 0.05 | 0.00% | — | — | -0.01% | 0.00% | 0.00% | 0.00 | — | 2.09 | 1.01 | — | 2308.00% | — | -9171.00% | -0.11% | 0.00 | -0.06% | 0.00% | 0.00% | 1690.13% | — | 14968.87 | — | -3.52 |
| APM | Aptorum Group Limited | $0.78 | 4.95M | +30,801% | — | — | — | -1.20 | 0.24 | — | -2.03 | -4.65 | 0.24 | 0.00% | — | — | -18.56% | -15.20% | -23.21% | 0.16 | -25.84 | 0.22 | 0.20 | -0.66 | 2581.00% | -10000.00% | -8459.00% | -23.24% | -0.27 | -4.77% | 0.00% | 0.00% | 0.00% | -2.00 | -6.39 | — | -6.61 |
| BGLC | BioNexus Gene Lab Corp. | $2.72 | 4.89M | +1,907% | +316% | -93% | — | -4.11 | 0.79 | 0.69 | -1.70 | — | 0.79 | 13.56% | -16.55% | -16.81% | -17.78% | -39.19% | -14.64% | 0.03 | -74.42 | 3.81 | 3.05 | 2.93 | -4118.00% | -266.00% | 2885.00% | -37.43% | -1.15 | -61.29% | 0.00% | 0.00% | 0.00% | -1.53 | -0.98 | 0.25 | 2.45 |
| CHEK | Check-Cap Ltd. | $1.68 | 9.83M | — | — | — | — | -0.19 | -3.24 | — | -0.49 | -0.43 | -3.24 | 0.00% | — | — | -226.19% | 1959.89% | -198.07% | -0.09 | -2883.22 | 0.15 | 0.15 | -0.01 | 4333.00% | — | -9995.00% | -0.17% | 0.00 | 0.60% | 0.00% | 0.00% | 0.00% | -0.18 | -570.68 | — | -861.86 |
| GELS | Gelteq Limited Ordinary S… | $0.76 | 6.95M | — | +137% | — | — | — | — | — | — | — | — | 100.00% | -3317.65% | -4011.86% | 0.00% | -28.47% | 0.00% | 0.27 | -2.90 | 0.27 | 0.14 | -1.10 | — | — | 40580.00% | — | -0.98 | -31.93% | — | — | — | — | — | — | — |
| MBIO | Mustang Bio, Inc. | $1.01 | 7.37M | — | — | — | — | -0.58 | -2.34 | — | -0.21 | — | -2.34 | 0.00% | — | — | 840.11% | 241.62% | -116.47% | -0.23 | 3249.00 | 0.68 | 0.57 | 0.40 | -5717.00% | — | -7699.00% | -125.80% | -0.90 | 169.70% | 6.74% | -3.90% | 31.27% | -0.19 | -0.27 | — | -65.53 |
| MRKR | Marker Therapeutics, Inc. | $1.48 | 15.98M | +3,230% | -2% | — | — | -1.26 | 0.73 | 2.04 | 0.51 | — | 0.73 | -104.33% | -168.69% | -162.82% | -65.81% | 1313.50% | -54.82% | 0.00 | — | 6.36 | 6.22 | 1.73 | -3834.00% | 9906.00% | -3364.00% | -81.00% | -3.15 | 1288.92% | 0.00% | 0.00% | 30.30% | 0.51 | 0.52 | -0.87 | -26.44 |
| RDGT | Ridgetech Inc. | $1.58 | 9.25M | +23,821% | -76% | +804% | — | 0.52 | 0.18 | 0.04 | 0.59 | — | 0.21 | 3.20% | -0.86% | 8.50% | 45.06% | -3.14% | 12.79% | 0.35 | — | 1.74 | 1.25 | -0.48 | -16280.00% | -2237.00% | -11551.00% | 11.89% | 0.04 | 1.92% | 0.00% | 0.00% | 478.51% | -2.83 | 4.63 | 0.02 | 1.00 |
| TNON | Tenon Medical, Inc. | $0.87 | 7.5M | +21,018% | +210,838% | — | — | -0.12 | 0.26 | 0.48 | 0.35 | — | 0.26 | 52.21% | -420.08% | -417.24% | -405.19% | -38777.46% | -168.93% | 0.07 | -404.88 | 4.39 | 3.96 | 0.47 | -8360.00% | 1192.00% | -1977.00% | -637.69% | -5.29 | -28349.30% | 0.00% | 0.00% | 350.78% | 0.33 | 0.45 | -1.38 | -13.04 |
| TRIB | Trinity Biotech plc | $0.72 | 7.47M | +6,885% | -61% | — | — | -0.39 | -0.35 | 0.20 | -6.39 | — | -0.14 | 34.83% | -34.38% | -51.64% | 107.52% | -42.24% | -39.07% | -2.86 | -2.21 | 1.28 | 0.62 | -5.65 | -4469.00% | 831.00% | 1533.00% | -115.03% | -0.13 | -28.45% | 0.00% | 0.00% | 0.00% | -5.10 | -7.58 | 1.75 | -0.99 |
| XAIR | Beyond Air, Inc. | $0.96 | 4.87M | +6,086% | +58% | — | — | -0.27 | 0.95 | 3.47 | -0.42 | — | 1.04 | -44.89% | -1202.08% | -1258.43% | -250.98% | -332.73% | -111.42% | 0.86 | -14.75 | 3.20 | 1.56 | -0.17 | -6210.00% | 21967.00% | -2859.00% | -342.82% | -7.64 | -329.47% | 0.00% | 0.00% | 0.00% | -0.40 | -0.40 | 4.76 | -17.17 |
About Advanced Biomed Inc. Common Stock
Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, a fully automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cells (CTCs) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product. The company also provides microfluidic biochips comprising A+Pre, AC-1000 CTC Enrichment, and A+CellScan chips that are designed to provide assay products and services to cancer patients. In addition, its immunochromogenic kits include the A+CTCE kit, which is used to identify epithelial circulating tumor cells and is determined by the immunochromogenicity of EpCAM, CK (pan), CD45, and CD14 antibodies; the A+CTCM kit, which is used to identify mesenchymal circulating tumor cells based on the immunochromogenicity of Vimentin, CD45, and CD14 antibodies; the A+EMT, which is used to identify epithelial-to-mesenchymal circulating tumor cells determined by the immunochromogenicity of cell-surface Vimentin, and CD45 and CD14 antibodies; and the A+CM, which is used to identify tumor-associated macrophages based on the immunochromogenicity of PD-L1, CD45, and CD14 antibodies. Further, the company is developing A+LCGuard for early screening of lung cancer. Additionally, it establishes and operates medical clinics in the People's Republic of China. The company was founded in 2014 and is headquartered in New York, New York.
- CEO
- Yi Lu
- Employees
- 40
- Beta
- 0.25
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $5.27) − 1 = — (DCF, example).